No Data
No Data
Express News | HC Wainwright & Co. Reiterates Buy on Compass Pathways, Maintains $120 Price Target
Buy Rating Affirmed for COMPASS Pathways Amid Progress in Pivotal Trials and Strong Financial Position
CCORF Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $48
Buy Rating Affirmed: COMPASS Pathways' Promising Clinical Trials Advance Psychedelic Therapeutics
Lykos Laying off 75% of Workforce Following FDA Rejection of Psychedelic Drug for PTSD
TD Cowen Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $23
No Data